Last reviewed · How we verify
NCT06065111: SOIT
Study of Osteogenesis Imperfecta Tendon
trial testing study tendon damage in osteogenesis imperfecta patients in Osteogenesis Imperfecta in 130 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Université Catholique de Louvain |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 13 September 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- study tendon damage in osteogenesis imperfecta patients
Conditions studied
- Osteogenesis Imperfecta — all drugs for Osteogenesis Imperfecta →
Sponsor
Université Catholique de Louvain — full company profile →
Who can join
Eligibility, any sex, with Osteogenesis Imperfecta. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities. However, other tissues rich in type I collagen can also be affected, such as teeth or vessel walls. In the literature, several case reports describe tendon ruptures in OI patients, but no original study has really addressed this issue, which is likely to impact the quality of life through a reduction in mobility and pain. Recent work carried out by the investigators shows an alteration of the osteotendinous unit in the osteogenesis imperfecta mouse (oim), a validated model of the most severe form of OI. Consequently, the project aims to study the damage of tendon and ligament in patients suffering from osteogenesis imperfecta.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06065111
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteogenesis Imperfecta
Currently open trials in the same condition.
- NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
- NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
- NCT05972551 — Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Oste · Phase 3 · recruiting
- NCT05927389 — Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta · NA · recruiting
- NCT06193642 — Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data · NA · active not recruiting
Other Université Catholique de Louvain trials
Trials by the same sponsor.
- NCT07453524 — Assessing Chronic Pain Patient Preferences · NA · not yet recruiting
- NCT07422909 — Bridging the Gap: Implementing BRIDGES · NA · not yet recruiting
- NCT07420231 — Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort · NA · not yet recruiting
- NCT07360223 — Internalized Symptoms in Adolescents With Autism Spectrum Disorder (ASD) and Typically Developing Adolescents : Gaining · not yet recruiting
- NCT07263971 — Birth Experience of Women Giving Birth in Belgium · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06065111 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université Catholique de Louvain
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06065111.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing